Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets

Cancer Discovery

Volumn 1, Issue 6, 2011, Pages 487-495

  Beltran, Himisha ^a   Rickman, David S ^a   Park, Kyung ^a   Chae, Sung Suk ^a   Sboner, Andrea ^b   MacDonald, Theresa Y ^a   Wang, Yuwei ^d   Sheikh, Karen L ^a   Terry, Stéphane ^a   Tagawa, Scott T ^a   Dhir, Rajiv ^e   Nelson, Joel B ^e   de la Taille, Alexandre ^f   Allory, Yves ^f   Gerstein, Mark B ^b,c   Perner, Sven ^g   Pienta, Kenneth J ^h,i   Chinnaiyan, Arul M ^i,j   Wang, Yuzhuo ^d   Collins, Colin C ^d   Gleave, Martin E ^d   Demichelis, Francesca ^a,k   Nanus, David M ^a   Rubin, Mark A ^a   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b YALE UNIVERSITY   (United States)

^c Yale University   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f HENRI MONDOR HOSPITAL   (France)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^j HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^k UNIVERSITY OF TRENTO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; DANUSERTIB; MYC PROTEIN; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFICACY; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MOUSE; NEUROENDOCRINE PROSTATE CANCER; NONHUMAN; POLYMERASE CHAIN REACTION; PROSTATE CANCER; RNA SEQUENCE; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; COHORT STUDIES; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84860168795     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-11-0130     Document Type: Article

References (28)

1. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 2007;34:22-9.
2. Wang W, Epstein JI. Small cell carcinoma of the prostate: a morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:65-71.
3. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
4. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011;24:820-8.
5. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009;15:4706-11.
6. Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010;23:1061-7.
7. Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol 2011;24:1120-7.
8. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
9. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-93.
10. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009;15:67-78.
11. Strieder V, Lutz W. Regulation of N-myc expression in development and disease. Cancer Lett 2002;180:107-19.
12. Hsu JY, Sun ZW, Li X, Reuben M, Tatchell K, Bishop DK, et al. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 2000;102:279-91.
13. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A 2005;102:731-6.
14. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45:2913-23.
15. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-25.
16. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008;100:815-25.
17. Tung WL, Wang Y, Gout PW, Liu DM, Gleave M. Use of irinotecan for treatment of small cell carcinoma of the prostate. Prostate 2011;71:675-81.
18. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45:586-92; discussion 92.
19. Berruti A, Mosca A, Porpiglia F, Bollito E, Tucci M, Vana F, et al. Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol 2007;178:838-43; quiz 1129.
20. Brawn PN, Speights VO. The dedifferentiation of metastatic prostate carcinoma. Br J Cancer 1989;59:85-8.
21. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715-30.
22. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005;47:147-55.
23. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007;14:531-47.
24. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 2009;69:603-9.
25. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899-905.
26. Bleuse JP, Meulenbeld HJ, Vinci EM, Raymond E, Vitali G, Santoro A, et al. Randomized phase II study of danusertib in 2nd line metastatic castration-resistant prostate cancer. J Clin Oncol 2011;29(suppl; abstr 4628).
27. Habegger L, Sboner A, Gianoulis TA, Rozowsky J, Agarwal A, Snyder M, et al. RSEQtools: a modular framework to analyze RNA-Seq data using compact, anonymized data summaries. Bioinformatics 2011;27:281-3.
28. Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin PC, et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res 2011;21:56-67.